University of Electronic Science and Technology of China   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Chengdu China (1956)

Organization Overview

First Clinical Trial
2008
NCT00700440
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Chengdu Women and Children's Center Hospital | China,Sichuan, School of Life Science and Technology,University of Electronic Science and Technology | School of Life Science and Technology, University of Electronic Science and Technology of China | Sichuan Cancer Hospital and Research Institute | Sichuan Cancer Hospital & Institute | SiChuan Province Tumor Hospital | University of Electronic Science and Technology | University of Electronic Science and Technology of China | University of Electronic Science and Technology of China (UESTC) | University of Electronic Science and Technology of China(UESTC) | University of Electronic Science and Technology, Sichuan

Active Ingredients

Drugs in Phase 4 Trials (6)

aprepitant (Emend) (1 trial)

kang fu (1 trial)

mycophenolate (CellCept) (1 trial)

olanzapine (zyprexa) (1 trial)

tacrolimus (prograf) (1 trial)

toripalimab (LOQTORZ) (5 trials)

Drugs in Phase 3 Trials (10)

131i-lipiodol (Lipiodol) (1 trial)

cisplatin (platinol) (9 trials)

docetaxel (taxotere) (3 trials)

epirubicin (ellence) (1 trial)

gelatin (1 trial)

lobaplatin (1 trial)

nedaplatin (1 trial)

paclitaxel (taxol) (8 trials)

pemetrexed (alimta) (4 trials)

sintilimab (4 trials)

Drugs in Phase 2 Trials (26)

almonertinib (1 trial)

anlotinib (3 trials)

atezolizumab (Tecentriq) (1 trial)

bevacizumab (avastin) (5 trials)

camrelizumab (2 trials)

carboplatin (paraplatin) (5 trials)

cetuximab (erbitux) (2 trials)

dactinomycin (cosmegen) (2 trials)

doxorubicin (Doxil) (1 trial)

epoetin (Epogen) (1 trial)

erlotinib (tarceva) (1 trial)

etoposide (vepesid) (1 trial)

gefitinib (iressa) (1 trial)

gemcitabine (gemzar) (1 trial)

hlx10 (1 trial)

icotinib (Conmana) (1 trial)

imatinib (gleevec) (1 trial)

lapatinib (tykerb) (6 trials)

niraparib (zejula) (1 trial)

nituzumab (2 trials)

penpulimab (1 trial)

sorafenib (nexavar) (2 trials)

tgrx-326 (1 trial)

tirelizumab (1 trial)

tislelizumab (1 trial)

yangzhengxiaoji (1 trial)

Drugs in Phase 1 Trials (2)

durvalumab (imfinzi) (1 trial)

oxytocin (syntocinon) (41 trials)

Drugs in Other Trials (9)

dexamethasone (1 trial)

flumazenil (mazicon ) (1 trial)

lidocaine (xylocaine) (1 trial)

losartan (cozaar) (5 trials)

modafinil (provigil) (1 trial)

netupitant (Akynzeo) (1 trial)

palonosetron (aloxi) (1 trial)

sodium chloride (1 trial)

vasopressin (vasostrict) (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anxiety Disorders (Phase 1)

Carcinoma (Phase 4)

Carcinoma, Hepatocellular (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Squamous Cell (Phase 4)

Digestive System Neoplasms (Phase 2)

Esophageal Neoplasms (Phase 3)

Esophageal Squamous Cell Carcinoma (Phase 4)

Facies (Phase 1)

Gastrointestinal Neoplasms (Phase 2)

Liver Diseases (Phase 2)

Liver Neoplasms (Phase 2)

Lung Diseases (Phase 2)

Lung Neoplasms (Phase 4)

Lymphatic Metastasis (Phase 3)

Nasopharyngeal Carcinoma (Phase 3)

Nasopharyngeal Neoplasms (Phase 2)

Nausea (Phase 4)

Neoplasms (Phase 2)

Nephrosis (Phase 4)

Nephrotic Syndrome (Phase 4)

Ovarian Neoplasms (Phase 2)

Parkinson Disease (Phase 2)

Rectal Neoplasms (Phase 2)

Respiratory Tract Diseases (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Syndrome (Phase 4)

Thoracic Neoplasms (Phase 2)

Vomiting (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 99
  • # of Trial APIs: 53